Previous 10 | Next 10 |
The following slide deck was published by Dicerna Pharmaceuticals, Inc. in conjunction with this Read more ...
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Q4 2018 Earnings Conference Call March 11, 2019 4:30 PM ET Company Participants Rebecca Peterson - Head of Corporate Communications Douglas Fambrough - President and Chief Executive Officer Jack Green - Chief Financial Officer Ral...
Dicerna Pharmaceuticals (NASDAQ: DRNA ) announces key events for 2019: More news on: Dicerna Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Dicerna Pharmaceuticals (NASDAQ: DRNA ): Q4 GAAP EPS of -$0.29 misses by $0.08 . More news on: Dicerna Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
— 2018 was a Milestone Year for Dicerna Across a Variety of Fronts, Including Data Readouts for Primary Hyperoxaluria, Business Development Collaborations and a Successful Follow-On Offering — — Company’s Robust Cash Position Provides Funds Beyond 2020 to ...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and year end 2018 financial results after market close on Monday, March 11, 2019. Man...
The following slide deck was published by Dicerna Pharmaceuticals, Inc. in conjunction with this Read more ...
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview at the following investor confer...
— Regina DeTore Paglia Joins Company as Senior Vice President of Human Resources — — Rebecca Peterson Hired as Head of Corporate Communications — — Hardean E. Achneck, M.D., Joins as Vice President, Head of Medical Development — Dic...
Introduction - good things may be happening here I stopped trading or commenting on Alexion ( ALXN ) in the first half of 2017, when there were countless uncertainties. ALXN was around $110 and was sold at a small loss. ALXN closed Wednesday at $125.18, lagging the market ( SPY ) and a major...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...